Published in Nat Med on July 05, 2009
Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant (2010) 2.37
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 2.23
Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med (2011) 1.97
Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant (2012) 1.54
LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest (2010) 1.41
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant (2014) 1.19
Transplantation tolerance through mixed chimerism. Nat Rev Nephrol (2010) 1.17
Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant (2013) 1.14
Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol (2013) 1.11
Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant (2011) 1.10
CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection. Am J Transplant (2016) 1.09
Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Curr Opin Organ Transplant (2010) 1.07
Advances in immunosuppression for renal transplantation. Nat Rev Nephrol (2010) 1.05
Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant (2012) 1.04
The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03
The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol (2012) 1.03
Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant (2009) 1.02
Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant (2012) 1.01
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol (2012) 1.00
Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest (2014) 0.99
LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant (2011) 0.97
Novel immunosuppressive agents in kidney transplantation. World J Transplant (2013) 0.96
Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant (2010) 0.96
T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old. Am J Transplant (2011) 0.91
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
Costimulatory pathways in transplantation. Semin Immunol (2011) 0.90
The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant (2014) 0.90
Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant (2012) 0.90
Heterogeneity within T Cell Memory: Implications for Transplant Tolerance. Front Immunol (2012) 0.89
Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev (2014) 0.86
Innate immunity and resistance to tolerogenesis in allotransplantation. Front Immunol (2012) 0.85
Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant (2012) 0.85
Antibody immunosuppressive therapy in solid organ transplant: Part II. MAbs (2010) 0.84
Effects of preexisting autoimmunity on heart graft prolongation after donor-specific transfusion and anti-CD154. Transplantation (2014) 0.84
Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection. J Am Soc Nephrol (2016) 0.84
Clinical transplantation tolerance. Semin Immunopathol (2011) 0.83
Memory T cells in organ transplantation: progress and challenges. Nat Rev Nephrol (2016) 0.83
New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo) (2014) 0.82
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells. Am J Transplant (2013) 0.81
Heterologous immunity triggered by a single, latent virus in Mus musculus: combined costimulation- and adhesion- blockade decrease rejection. PLoS One (2013) 0.80
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells? Front Immunol (2015) 0.80
Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance. Curr Opin Organ Transplant (2015) 0.80
Novel therapies for memory cells in autoimmune diseases. Clin Exp Immunol (2015) 0.79
T Cell Cosignaling Molecules in Transplantation. Immunity (2016) 0.79
Lymphodepletional strategies in transplantation. Cold Spring Harb Perspect Med (2013) 0.78
B Cell Depletion With an Anti-CD20 Antibody Enhances Alloreactive Memory T Cell Responses After Transplantation. Am J Transplant (2015) 0.78
Roles of CD48 in regulating immunity and tolerance. Clin Immunol (2016) 0.78
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology (2010) 0.78
Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77
Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. Am J Transplant (2015) 0.77
T-cell co-stimulatory blockade in kidney transplantation: back to the bench. Kidney Int Suppl (2011) (2011) 0.77
Pathogen Stimulation History Impacts Donor-Specific CD8(+) T Cell Susceptibility to Costimulation/Integrin Blockade-Based Therapy. Am J Transplant (2015) 0.77
The Evolving Roles of Memory Immune Cells in Transplantation. Transplantation (2015) 0.77
Primate models in organ transplantation. Cold Spring Harb Perspect Med (2013) 0.77
Gazing into a crystal ball to predict kidney transplant outcome. J Clin Invest (2010) 0.77
Studies Introducing Costimulation Blockade for Vascularized Composite Allografts in Nonhuman Primates. Am J Transplant (2015) 0.77
T-cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med (2013) 0.77
Homeostatic expansion as a barrier to lymphocyte depletion strategies. Curr Opin Organ Transplant (2014) 0.76
Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One (2016) 0.76
Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight (2016) 0.76
Viewing transplantation immunology through today's lens: new models, new imaging, and new insights. Biol Blood Marrow Transplant (2012) 0.75
The CD8 T-cell response during tolerance induction in liver transplantation. Clin Transl Immunology (2016) 0.75
Cross-talk between T and B Cells in the Germinal Center following Transplantation. Transplantation (2016) 0.75
Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. Transplantation (2016) 0.75
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? Immunotherapy (Los Angel) (2015) 0.75
Role of Memory T Cells in Allograft Rejection and Tolerance. Front Immunol (2017) 0.75
Development and homeostasis of T cell memory in rhesus macaque. J Immunol (2002) 6.88
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest (2003) 4.14
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75
Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med (1993) 2.62
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 2.12
Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol (2007) 1.42
Crossing the bridge: large animal models in translational transplantation research. Immunol Rev (2003) 1.36
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation (1998) 1.14
IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant (2005) 1.13
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol (2003) 0.96
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest (2003) 4.14
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med (2006) 2.55
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A (2007) 2.39
Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med (2006) 2.21
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation (2014) 2.00
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain (2009) 1.91
Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev (2003) 1.76
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood (2011) 1.73
Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med (2007) 1.68
APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation (2016) 1.68
Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev (2009) 1.66
Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant (2003) 1.61
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol (2012) 1.60
Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. Liver Transpl (2006) 1.57
Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol (2002) 1.55
iChoose Kidney: A Clinical Decision Aid for Kidney Transplantation Versus Dialysis Treatment. Transplantation (2016) 1.49
Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest (2004) 1.48
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Late priming and variability of epitope-specific CD8+ T cell responses during a persistent virus infection. J Immunol (2005) 1.47
Dynamic regulation of T cell immunity by CD43. J Immunol (2002) 1.45
LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest (2010) 1.41
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation (2002) 1.40
Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996. J Immunol (2011) 1.39
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol (2010) 1.38
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol (2005) 1.36
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation (2004) 1.31
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood (2003) 1.25
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol (2009) 1.21
Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant (2002) 1.19
Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant (2005) 1.19
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant (2005) 1.13
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation (2011) 1.12
Induction immunosuppression. Transplantation (2006) 1.10
Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation (2007) 1.10
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies (2004) 1.09
Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest (2006) 1.08
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 1.08
Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Curr Opin Organ Transplant (2010) 1.07
PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J Immunol (2008) 1.07
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging (2010) 1.06
A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection. J Immunol (2008) 1.05
Objective, real-time, intraoperative assessment of renal perfusion using infrared imaging. Am J Transplant (2003) 1.04
Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol (2002) 1.04
Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood (2007) 1.04
Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation. Transplantation (2004) 1.03
Costimulation requirements for antiviral CD8+ T cells differ for acute and persistent phases of polyoma virus infection. J Immunol (2006) 1.03
Induction of transplantation tolerance in non-human primate preclinical models. Philos Trans R Soc Lond B Biol Sci (2005) 1.02
Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant (2009) 1.02
Long-term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion. Am J Transplant (2003) 1.00
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood (2011) 0.98
Glial cell line-derived neurotrophic factor increases beta-cell mass and improves glucose tolerance. Gastroenterology (2008) 0.98
Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade. Proc Natl Acad Sci U S A (2011) 0.97
Measuring symptom experience of side-effects of immunosuppressive drugs: the Modified Transplant Symptom Occurrence and Distress Scale. Transpl Int (2008) 0.97
Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol (2011) 0.97
Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol (2005) 0.96
Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol (2004) 0.96
Expansion of effector memory TCR Vbeta4+ CD8+ T cells is associated with latent infection-mediated resistance to transplantation tolerance. J Immunol (2008) 0.95
Combined costimulatory and leukocyte functional antigen-1 blockade prevents transplant rejection mediated by heterologous immune memory alloresponses. Transplantation (2012) 0.95
CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes (2008) 0.94
Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol (2003) 0.94
The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol (2004) 0.93
IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. J Immunol (2009) 0.93
Costimulation blockade: towards clinical application. Front Biosci (2008) 0.93
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant (2013) 0.93